Did You Know...
...Chester Carlson was a patent agent who tired of having to make multiple copies of patent applications using the only duplication method available at the time: carbon paper. In 1959 he came up with a new copying system and took it to IBM for evaluation. The "experts" at IBM determined potential sales to be only 5,000 units because people wouldn't want to use a bulky machine when they had carbon paper. Carlson's invention was the xerography process, the company founded on the system is Xerox.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7943173 | Pharmaceutical combinations of oxycodone and naloxone Disclosed in certain embodiments is a pharmaceutical composition comprising from 10 to 40 mg of oxycodone or a pharmaceutically acceptable salt thereof and 0.65 to 0.90 mg naloxone or a pharmaceutically acceptable salt thereof. ... | 05/17/2011 |
| 7943174 | Controlled release hydrocodone formulations A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to rende... | 05/17/2011 |
| 7914818 | Opioid agonist formulations with releasable and sequestered antagonist Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and me... | 03/29/2011 |
| 7846476 | Once-a-day oxycodone formulations The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to ... | 12/07/2010 |
| 7842311 | Tamper-resistant oral opioid agonist formulations Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact. ... | 11/30/2010 |
| 7842309 | Tamper-resistant oral opioid agonist formulations Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact. ... | 11/30/2010 |
| 7842307 | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effecti... | 11/30/2010 |
| 7790215 | Sustained-release gel coated compositions Disclosed in certain embodiments is a coating comprising a pharmaceutically acceptable mixture of gelatin and hydrophobic polymer. ... | 09/07/2010 |
| 7718192 | Tamper-resistant oral opioid agonist formulations Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact. ... | 05/18/2010 |
| 7682632 | Tamper-resistant oral opioid agonist formulations Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact. ... | 03/23/2010 |
| 7658939 | Tamper-resistant oral opioid agonist formulations Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact. ... | 02/09/2010 |
| 7514100 | Controlled release hydrocodone formulations A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. ... | 04/07/2009 |
| 7510727 | Melt-extrusion multiparticulates A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length ... | 03/31/2009 |
| 7316821 | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated ... | 01/08/2008 |
| 7270831 | Orally administrable opioid formulations having extended duration of effect Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains ... | 09/18/2007 |
| 7144587 | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and a bittering agent in an effective amount to impart a bitter taste to an abuser upon administration of the dosage f... | 12/05/2006 |
| 7141250 | Pharmaceutical formulation containing bittering agent Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of a bittering agent to impart a bitter taste to an abuser upon administration of said dosage form after tam... | 11/28/2006 |
| 7070806 | Controlled release formulations coated with aqueous dispersions of acrylic polymers A stable solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic acrylic polymer includes a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally... | 07/04/2006 |
| 7060293 | Powder-layered oral dosage forms An oral dosage form of morphine is formulated by powder-layering an homogeneous mixture of morphine sulfate and hydrous lactose impalpable onto inert beads to obtain a multiparticulate product. A plurality of the powder-layered beads may be administered either in im... | 06/13/2006 |
| 6905709 | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated ... | 06/14/2005 |
| 6743442 | Melt-extruded orally administrable opioid formulations Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques are disclosed. ... | 06/01/2004 |
| 6733783 | Controlled release hydrocodone formulations A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. ... | 05/11/2004 |
| 6716449 | Controlled-release compositions containing opioid agonist and antagonist Controlled-release dosage forms containing an opioid agonist; an opioid antagonist; and a controlled release material release during a dosing interval an analgesic or sub-analgesic amount of the opioid agonist along with an amount of the opioid antagonist effective ... | 04/06/2004 |
| 6706281 | Melt-extrusion multiparticulates A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length ... | 03/16/2004 |
| 6696088 | Tamper-resistant oral opioid agonist formulations Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist ... | 02/24/2004 |
| 6673367 | Controlled/modified release oral methylphenidate formulations The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference st... | 01/06/2004 |
| 6645527 | Stabilized sustained release tramadol formulations A stabilized sustained release oral solid dosage form which includes an effective amount of tramadol or a pharmaceutically acceptable salt thereof dispersed in a matrix of a hydrophobic material comprising a wax-like substance which was melted or softened... | 11/11/2003 |
| 6572885 | Orally administrable opioid formulations having extended duration of effect Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesi... | 06/03/2003 |
| 6387404 | Immediate release tablet cores of insoluble drugs having sustained-release coating A controlled release tablet for oral administration is disclosed which has a tablet core including an insoluble therapeutically active agent having an aqueous solubility of less than or equal to about 5 mg/ml in a sufficient amount to render a therapeutic... | 05/14/2002 |
| 6335033 | Melt-extrusion multiparticulates A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles hav... | 01/01/2002 |
| 6316031 | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing ... | 11/13/2001 |
| 6306438 | Stabilized sustained release tramadol formulations A stabilized sustained release oral solid dosage form which includes an effective amount of tramadol or a pharmaceutically acceptable salt thereof dispersed in a matrix of a hydrophobic material comprising a wax-like substance which was melted or softened... | 10/23/2001 |
| 6294195 | Orally administrable opioid formulations having extended duration of effect Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesi... | 09/25/2001 |
| 6261599 | Melt-extruded orally administrable opioid formulations Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques disclosed.... | 07/17/2001 |
| 6210714 | Immediate release tablet cores of acetaminophen having sustained-release coating A controlled release tablet for oral administration is disclosed which has a tablet core including an insoluble therapeutically active agent having an aqueous solubility of less than or equal to about 5 mg/ml in a sufficient amount to render a therapeutic... | 04/03/2001 |
| 6143353 | Controlled release formulations coated with aqueous dispersions of acrylic polymers A stable solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic acrylic polymer includes a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent... | 11/07/2000 |
| 6129933 | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing ... | 10/10/2000 |
| 6103261 | Opioid formulations having extended controlled release Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, whe... | 08/15/2000 |
| 6077533 | Powder-layered oral dosage forms An oral dosage form of morphine is formulated by powder-layering an homogeneous mixture of morphine sulfate and hydrous lactose impalpable onto inert beads to obtain a multiparticulate product. A plurality of the powder-layered beads may be administered e... | 06/20/2000 |
| 6024982 | Immediate release tablet cores of insoluble drugs having sustained-release coating A controlled release tablet for oral administration is disclosed which has a tablet core including an insoluble therapeutically active agent having an aqueous solubility of less than or equal to about 5 mg/ml in a sufficient amount to render a therapeutic... | 02/15/2000 |
